Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has provided an update.
Jenscare Scientific Co., Ltd. has convened its 2025 annual general meeting for 28 May 2026 in Ningbo, Zhejiang, where shareholders will review the board report, audited consolidated financial statements, annual report, and profit distribution plan for 2025, as well as decide on director remuneration and the re-appointment of Ernst & Young as auditor for 2026. The company will also seek shareholder approval for a special mandate authorizing the board to issue convertible bonds and up to 20% additional share capital, providing funding flexibility for future growth and potentially affecting capital structure and shareholder dilution.
If approved, the issue mandate will empower the board to determine detailed terms of any new securities, including pricing, issuance method, target investors, and use of proceeds, and to engage professional advisers and enter related agreements. This expanded authority is intended to streamline the company’s access to capital markets under prevailing conditions, supporting its strategic and operational needs while concentrating key financing decisions at the board level.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a medical technology company based in the People’s Republic of China and listed in Hong Kong. It focuses on the development and commercialization of innovative medical devices, serving the healthcare market with an emphasis on advanced clinical solutions for patients in China and potentially broader international markets.
Average Trading Volume: 189,521
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.55B
For a thorough assessment of 9877 stock, go to TipRanks’ Stock Analysis page.